The ENHANCE Phase 3b clinical trial is evaluating the safety and efficacy of a modified treatment regimen of Briumvi for ...

Tolebrutinib slows disability progression in adults with nonrelapsing secondary progressive multiple sclerosis (MS).

The CAR T-cell therapy KYV-101 is safe, and showed preliminary signs of efficacy in patients with progressive forms of MS in ...

Dr Pavan Bhargava gives insights on earlier diagnosis, ocrelizumab safety in pregnancy, and promising anti-aging effects of diet in RRMS.

Researchers at the VIB-UGent Center for Medical Biotechnology have discovered a promising strategy to improve treatment ...

Tolebrutinib, a brain-penetrant BTK inhibitor, may fill a significant unmet need by delaying disability progression in patients with non-relapsing secondary progressive multiple sclerosis.

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive ...

Tolebrutinib, a novel BTK inhibitor that targets neuroinflammation, slowed disability progression by 31% in nrSPMS, a phase 3 ...